Cargando…

Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors

The design of multitarget drugs (MTDs) has become an innovative approach for the search of effective treatments in complex diseases such as cancer. In this work, we communicate our efforts in the design of multi-targeting histone deacetylase (HDAC) and protein kinase CK2 inhibitors as a novel therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez, Regina, Di Geronimo, Bruno, Pastor, Miryam, Zapico, José María, Coderch, Claire, Panchuk, Rostyslav, Skorokhyd, Nadia, Maslyk, Maciej, Ramos, Ana, de Pascual-Teresa, Beatriz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180456/ https://www.ncbi.nlm.nih.gov/pubmed/32218358 http://dx.doi.org/10.3390/molecules25071497

Ejemplares similares

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Tissue-protective activity of selenomethionine and D-panthetine in B16 melanoma-bearing mice under doxorubicin treatment is not connected with their ROS scavenging potential
por: Panchuk, Rostyslav R., et al.
Publicado: (2017)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The Link between Protein Kinase CK2 and Atypical Kinase Rio1
por: Kubiński, Konrad, et al.
Publicado: (2017)

Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs)
por: Rangasamy, Loganathan, et al.
Publicado: (2019)

Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study
por: Panchuk, Rostyslav, et al.
Publicado: (2014)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase Rio1
por: Kubiński, Konrad, et al.
Publicado: (2016)

Cannabimimetic N-Stearoylethanolamine as “Double-Edged Sword” in Anticancer Chemotherapy: Proapoptotic Effect on Tumor Cells and Suppression of Tumor Growth versus Its Bio-Protective Actions in Complex with Polymeric Carrier on General Toxicity of Doxorubicin In Vivo
por: Panchuk, Rostyslav, et al.
Publicado: (2023)

Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells
por: Świętek, Małgorzata, et al.
Publicado: (2020)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Antioxidants selenomethionine and D-pantethine decrease the negative side effects of doxorubicin in NL/Ly lymphoma-bearing mice
por: Panchuk, Rostyslav R., et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach
por: Ranganna, Kasturi, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Mitotic Activation of a Novel Histone Deacetylase 3-Linker Histone H1.3 Protein Complex by Protein Kinase CK2
por: Patil, Hemangi, et al.
Publicado: (2016)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

Design and Synthesis of Water-Soluble and Potent MMP-13 Inhibitors with Activity in Human Osteosarcoma Cells
por: Zapico, Jose Maria, et al.
Publicado: (2021)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

Unveiling a New Selenocyanate as a Multitarget Candidate with Anticancer, Antileishmanial and Antibacterial Potential
por: Ramos-Inza, Sandra, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
por: Lemos, Miguel, et al.
Publicado: (2020)

Aryl Urea Based Scaffolds for Multitarget Drug Discovery in Anticancer Immunotherapies
por: Martín-Beltrán, Celia, et al.
Publicado: (2021)

Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents
por: Pla-López, Alberto, et al.
Publicado: (2022)

Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors
por: Singha, Manali, et al.
Publicado: (2022)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vbvb8vvibdovm4hgifp3q4m0k5